Table 1.
Clinical characteristics of patients with lung adenocarcinoma
| Categories | Cohort N (n=32) |
Cohort T (n=418) |
P-value |
|---|---|---|---|
| Age (years), mean ± SD | 65.0±10.2 | 64.6±10.0 | 0.823 |
| Sex, n (%) | 0.714 | ||
| Male | 16 (50.0) | 195 (46.7) | |
| Female | 16 (50.0) | 223 (53.3) | |
| Race, n (%) | 0.099 | ||
| Asian | 0 (0.0) | 6 (1.4) | |
| White | 27 (84.4) | 314 (75.1) | |
| African | 5 (15.6) | 46 (11.0) | |
| NA | 0 (0.0) | 52 (12.5) | |
| Pathologic Stage, n (%) | 0.811 | ||
| Stage I | 20 (62.5) | 226 (54.1) | |
| Stage II | 7 (21.8) | 93 (22.2) | |
| Stage III | 5 (15.6) | 70 (16.7) | |
| Stage IV | 0 (0.0) | 22 (5.3) | |
| NA | 0 (0.0) | 7 (1.7) | |
| Pathologic T, n (%) | 0.900 | ||
| T1 | 13 (40.6) | 137 (32.8) | |
| T2 | 16 (50.0) | 223 (53.3) | |
| T3 | 2 (6.3) | 39 (9.3) | |
| T4 | 1 (3.1) | 16 (3.8) | |
| TX | 0 (0.0) | 3 (0.8) | |
| Pathologic N, n (%) | 0.520 | ||
| N0 | 21 (65.6) | 269 (64.4) | |
| N1 | 4 (12.5) | 75 (17.9) | |
| N2 | 5 (15.6) | 62 (14.8) | |
| N3 | 0 (0.0) | 2 (0.5) | |
| NX | 2 (6.3) | 9 (2.2) | |
| NA | 0 (0.0) | 1 (0.2) | |
| Pathologic M, n (%) | 0.152 | ||
| M0 | 18 (56.3) | 284 (68.0) | |
| M1 | 0 (0.0) | 21 (5.0) | |
| MX | 14 (43.8) | 110 (26.3) | |
| NA | 0 (0.0) | 3 (0.7) | |
| Smoking status, n (%) | 0.113 | ||
| Nonsmoker | 3 (9.7) | 67 (16.0) | |
| Reformed smoker | 14 (43.8) | 235 (56.2) | |
| Current smoker | 13 (40.6) | 104 (24.9) | |
| NA | 2 (5.9) | 12 (2.9) | |
| Vital status, n (%) | 0.376 | ||
| Alive | 23 (71.9) | 268 (64.1) | |
| Dead | 9 (28.1) | 150 (35.9) |
Notes: MX, metastasis status unknown; n, number of patients; NX, regional lymph node unknown; TX, tumor invasion unknown.
Abbreviations: NA, not available; SD, standard deviation.